In acute myeloid leukemia (AML), SWI/SNF chromatin remodeling complexes sustain leukemic identity by driving high levels of MYC. Previous studies have implicated the hematopoietic transcription factor PU.1 (SPI1) as an important target of SWI/SNF inhibition, but PU.1 is widely regarded to have pioneer-like activity. As a result, many questions have remained regarding the interplay between PU.1 and SWI/SNF in AML as well as normal hematopoiesis. Here we found that PU.1 binds to most of its targets in a SWI/SNF-independent manner and recruits SWI/SNF to promote accessibility for other AML core regulatory factors, including RUNX1, LMO2, and MEIS1. SWI/SNF inhibition in AML cells reduced DNA accessibility and binding of these factors at PU.1 sites and redistributed PU.1 to promoters. Analysis of nontumor hematopoietic cells revealed that similar effects also impair PU.1-dependent B-cell and monocyte populations. Nevertheless, SWI/SNF inhibition induced profound therapeutic response in an immunocompetent AML mouse model as well as in primary human AML samples. In vivo, SWI/SNF inhibition promoted leukemic differentiation and reduced the leukemic stem cell burden in bone marrow but also induced leukopenia. These results reveal a variable therapeutic window for SWI/SNF blockade in AML and highlight important off-tumor effects of such therapies in immunocompetent settings. Significance: Disruption of PU.1-directed enhancer programs upon SWI/SNF inhibition causes differentiation of AML cells and induces leukopenia of PU.1-dependent B cells and monocytes, revealing the on- and off-tumor effects of SWI/SNF blockade.
The emergence of SARS-CoV-2, the causative agent of COVID-19, has highlighted the need for advanced antiviral strategies. Targeting the coronaviral methyltransferase nsp14, which is essential for RNA capping, offers a promising approach for the development of small-molecule inhibitors. We designed and synthesized a series of adenosine 5′-carboxamide derivatives as potential nsp14 inhibitors and identified coumarin analogs to be particularly effective. Structural modifications revealed the importance of the 5′-carboxyl moiety for the inhibitory activity, showing superior efficacy compared to other modifications. Notably, compound 18l (HK370) demonstrated high selectivity and favorable in vitro pharmacokinetic properties and exhibited moderate antiviral activity in cell-based assays. These findings provide a robust foundation for developing targeted nsp14 inhibitors as a potential treatment for COVID-19 and related diseases.
A stable C7 sulfonyl chloride intermediate allows the first general synthesis of C7-sulfonamide 7-deazaadenosines, opening new directions for nucleoside functionalization and scaffold design.
Herein, we report a revised von Richter reaction‐based intramolecular cyclization approach for synthesizing polysubstituted cinnolines from 2‐aminoalkyne precursors. Our methodology addresses key limitations of the former approach, most notably the pronounced hydrolytic instability of 4‐halocinnoline intermediates. By exploring the influence of various substituents and implementing strictly anhydrous cyclization conditions or incorporating a stabilizing phenyl group at position 3, we minimized hydrolysis and expanded the reaction scope to a wide range of polysubstituted cinnolines. The resulting scaffolds retain strategically positioned halogens at C‐4, enabling late‐stage functionalization, including one‐pot nucleophilic substitution and cross‐coupling strategies. We utilized this method to synthesize several complex cinnoline derivatives, among them 45 . Profiling of 45 against a kinase panel revealed selective inhibition of multiple tyrosine kinases, underscoring both the practical value of the optimized method and the potential of cinnoline as a promising scaffold in kinase inhibitor development.